NCT02301039
|
Phase II |
Pembrolizumab
|
A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas |
Active, not recruiting |
NCT02584309
|
Phase II |
dexrazoxane
Doxorubicin + Olaratumab
|
Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma |
Recruiting |
NCT02584647
|
Phase Ib/II |
Pexidartinib + Sirolimus
|
Combination of PLX3397 and Sirolimus in Unresectable Sarcoma (Phase 1) and Malignant Peripheral Nerve Sheath Tumors (Phase 2) |
Recruiting |
NCT02601209
|
Phase Ib/II |
Pazopanib
Sapanisertib
|
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma |
Active, not recruiting |
NCT02978859
|
Phase II |
MGCD516
|
MGCD516 in Advanced Liposarcoma and Other Soft Tissue Sarcomas |
Recruiting |
NCT02986919
|
Phase II |
CPI-0610
|
Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors |
Withdrawn |
NCT02987959
|
Phase II |
Sapanisertib
|
Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas |
Recruiting |
NCT03009201
|
Phase I |
Doxorubicin + Ribociclib
|
Ribociclib and Doxorubicin Hydrochloride in Treating Patients Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery |
Recruiting |